ResMed CEO on how wearables, GLP-1s will impact sleep apnea device sales

NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post-presentation cocktail reception. If the sleep tech magnate could have used more shuteye he didn’t show it.

Farrell leaned forward enthusiastically to inspect data from a reporter’s Apple smartwatch showing that it hadn’t detected signs of sleep apnea.

advertisement

“Luckily for you, that’s not flashing red,” he joked. “If it was, I’d be selling you a CPAP.”

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe